Ann: Letter to Shareholders, page-35

I have read the letter once and I couldn’t disagree with you more strongly. I suggest that the premise -
“BIT 225 uniquely combines direct antiviral activity with restoration of normal immune regulation through it’s targeting of viroporin activity “ is without any foundation whatsoever.
How can they possibly deduce that?.
Also -
“importantly, in the 010 trial blood virus levels decreased more quickly in people on BiT225+ART compared to ART alone. This suggests that BIT225 is having an on a critical phase of viral decay when reservoirs are established “. What!!!, how do you work that link out?, it mealy suggests it assists the ART drugs in eliminating the virus - has got no tangible link to reservoirs.
I feel Biotron is making unsubstantiated premises about BIT225 and the depletion of viral loads within reservoirs.